No.5参考文献「ワクチン、神経発達、及び自閉症スペクトル疾患」ラッセル L. ブレイロック博士5

No.5「ワクチン、神経発達、及び自閉症スペクトル疾患」ラッセル L. ブレイロック博士5

References
1.Money J et al. Autism and autoimmune disease: A family study. J Autism Child Schizophr 1971; 1: 146-160.
2.Comi A. et al. Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J Child Neurology 1999; 14: 388-394.
3.Sweetwen TL et al. Increased prevalence of familial autoimmunity in probands with pervasive developmental disorders. Pediatrics 2003: 112: 420.
4.Creen LA et al. Maternal autoimmune disease, asthma and allergies, and childhood autism spectrum disorders: a case-control study. Arch Pediatr 2005;159: 151-157.
5.Dalton P et al. Maternal antibodies associated with autism and language disorders. Ann Neurol 2003;53: 533-537.
6.Singh VK, Rivas WH. Prevalence of serum antibodies to caudate nucleus in autistic children. Neuroscience Lett 2004; 355: 53-56.
7.Singh VK et al. Antibodies to myelin basic protein in children with autistic behavior. Brain Behavior Immunol 1993; 7: 97-103.
8.Singer HS et al. Antibrain antibodies in children with autism and their unaffected siblings. J Neuroimmunol 2006; 178: 149-155.
9.Singh VK et al. Circulating autoantibodies to neural and glial filament proteins in autism. Pediatr Neurol 1997; 17: 88-90.
10.el-Fawal HA e al. Exposure to methylmercury results in serum autoantibodies to neurotypic and gliaotypic proteins. Neurotoxicology 1996; 17: 531-539.
11.Havarinasab S et al. Immunosuppressive and autoimmune effects of thimerosal in mice. Toxicol Appl Pharmacol 2005; 204; 109-121.
12.Hornig M, Chian D, Lipkin WJ. Neurotoxic effect of postnatal thimerosal are mouse strain dependent. Mol Psychiatry 2004; 9: 833-845.
13.Tishler M, Shoenfeld Y. Vaccination may be associated with autoimmune disease. Isr Med Assoc J 2004; 6: 430-432.
14.Shoenfeld T, Aron-Maor A. Vaccination and autoimmunity-‘vaccinosis’ a dangerous liaison? J Autoimmunity 2000; 14: 1-10.
15.Vojdam A et al. Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A. J Neuroimmunol 2002; 129: 168-177.
16.Lucarelli S et al. Food allergy and infantile autism. Panminerva Med 1995; 37: 137-141.
17.O’Banion D et al. Disruptive behavior: a dietary approach. J Autism Child Schizophr 1978; 8: 325-337.
18.Vojdani A et al. Immune response to dietary proteins, gliadin and cerebellar peptides in children with autism. Nutr Neuroscience 2004; 7: 151-161.
19.McGeer PL and McGeer EG. Autotoxicity and Alzheimer Disease. 2000; 57; 289-290.
20.Malek-Ahmadi P. Cytokines and etiopathogenesis of pervasive developmental disorders. Med Hypothesis 2001; 56: 321-324.
21.Weizman A et al. Abnormal responses to brain tissue antigen in the syndrome of autism. Am J Psychiatry 1982; 139; 1462-1465.
22.Lee SC et al. Cytokine production by human fetal microglia and astrocytes. Differential induction by liposaccharide and IL-1beta. J Immunol 1993; 150: 2659-2667.
23.Bauer S et al. The neuropoetic cytokine family in development, plasticity, disease and injury. Nature Reviews/Neuroscience 2007; 8: 221-232.
24.Boulanger LM, Shatz CJ. Immune signaling in neural development, synaptic plasticity and disease. Nature Reviews/Neuroscience 2004; 5: 521-531.
25.Agrawal A et al. Thimerosal induces TH2 responses via influencing cytokine secretion by human dendritic cells. J Leukocyte Biol 2007; 81: 1-9.
26.Kidd P. Th1/Th2 balance: The hypothesis, its limitations, and implication in health and disease. Altern Medicine Rev 2003; 8: 223-246.
27.Martin OC et al. Hepatitis B immunization induces higher antibody and memory Th2 responses in new-borns than adults. Vaccine 2004; 22: 511-519.
28.Cohly HH, Panja A. Immunologic findings in autism. In Rev Neurobiol 2005; 71: 317-341.
29.Singh VK. Plasma increase of interleukin-12 and interferon-gamma. Pathological significance in autism. J Neuroimmunol 1996; 66: 143-145.
30.Jyonouchi H et al. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol 2001; 120: 170-179.
31.Pandey RS et al. Autoimmune model of schizophrenia with special reference to antibrain antibodies. Biol Psychiatry 1981;16: 1123-1136.
32.Zhang XY et al Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr Res 2002; 57: 247-258.
33.Turner W et al. Measles associated encephalopathy in children with renal transplants. Am J Transplant 2006; 6: 1459-1465.
34.Larner AJ, Farmer SF. Myelopathy following influenza vaccination in inflammatory disorder treated with chronic immunosuppression. Eu J Neurol 2000; 7: 731-733.
35.Kerdile YM et al. Immunosuppression by measles virus: role of viral proteins. Rev Med Virol 2006; 16: 49-63.
36.Abernathy RS, Spink WW. Increased susceptibility of mice to bacterial endotoxins induced by pertussis vaccine. Fed Proc 1956; 15: 580.
37.Auwaerter PD et al. Changes within T-cell receptor V beta subsets in infants following measles vaccinations. Clin Immunol Immunopathol 1996; 79: 163-167.
38.Hussey GD et al. The effect of Edmonston-Zagreb and Schwartz measles vaccines on immune responses in infants. J Infect Dis 1996; 173: 1320-1326.
39.Hirsch RL et al. Measles virus vaccination of measles seropositive individuals suppresses lymphocyte proliferation and chemotactic factor production. Clin Immunol Immunopath 1981; 21: 341-350.
40.Daum RS et al. Decline in serum antibody to the capsule of Haemophilus influenza type b in the immediate postimmunization period. J Pediatrics 1989;1114: 742-747.
41.Pukhalsky AL et al. Cytokine profile after rubella vaccine inoculation: evidence of the immunosuppressive effect of vaccination. Mediators Inflammation 2003; 12: 203-207.
42.Miller NZ. Vaccine Safety Manuel: For Concerned Families and Health Practioners. New Atlantean Press, NM, 2008.
43.Pichichero ME et al. Pathogen shifts and changing cure rates for otitis media and tonsillopharyngitis. Clin Pediatr 2006; 45: 493-502.
44.Moore MR et al. Impact of conjugate vaccine on community wide coverage of nonsusceptible Streptococcus in Alaska. J Inf Dis 2004; 190: 2031-2038.
45.Pichichero ME, Cary JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 2007; 298: 1772-1778.
46.Strunecka A., Patocka J, Blaylock RL et al. Fluoride interactions: From molecules to disease. Current Signal Transduction Therapy 2007; 2
47.Block ML, Zecca L, Hong J-S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature Reviews/Neuroscience 2007; 8: 57-69.
48.Mandu P, Brown GC, Activation of microglial NADPH oxidase is synergistic with glial NOS expression in inducing neuronal death: a duel-key mechanism of inflammatory neurodegeneration. 2005; 2: 20.
49.Cagnin A et al. In vivo visualization of activated glia by [11C] (R)- PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. Brain 2001; 124: 2014-2027.
50.Lemstra AW et al. Microglia activation in sepsis: a case-control study. J Neuroinflamm 207; 4: 4
51.Buttini M, Lumonta S, Boddeke HW. Peripheral administration of lipopolysaccharide induces activation of microglial cell in rat brain. Neurochem Int 1996; 29: 25-35.
52.Cunningham C et al. Central and systemic endotoxin challenges exacerbate the local inflammatory responses and increased neuronal death during chronic neurodegeneration. J Neurosci 2005; 25: 9275-9284.
53.Godbout JP et al. Exaggerated neuroinflammatory and sickness behavior in aged mice following activation of the peripheral innate immune system. FASEB J 2005;19: 1329-1331.
54.Vargas DL et al. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005; 57: 67-81.
55.Blaylock RL. Central role of excitotoxicity in autism. JANA 2003;6: 7-19.
56.Lewine JD et al. Magnetoencephalographic patterns of epileptiform activity in children with regressive autism spectrum disorders. Pediatrics 1999; 104: 405-415.
57.Auvin S et al. Inflammation exacerbates seizure-induced injury in the immature brain. Epilepsia 2007; 48: 27-34.
58.Rizzi M et al. Glia activation and cytokines increased in rat hippocampus by kainic acid-induced status epilepticus during postnatal development. Neurobiol Dis 2003; 4: 94-103.
59.Eastman CL et al. Increased brain quinolinic acid production in mice infected with hamster neurotropic measles virus. Exp Neurol 1994; 125: 119-124.
60.Heyes MP et al. Human microglia convert L-tryptophan into neurotoxin quinolinic acid. Biochem J 1996; 320: 595-597.
61.Ida T et al. Cytokine-induced enhancement of calcium-dependent glutamate release from astrocytes mediated by nitric oxide. Neurosci Lett 2008; 432: 232-236.
62.Ye GL et al. AMPA and NMDA receptor-mediated currents in developing dentate granule cells. Brain Res Dev Brain Res 2005; 155: 26-32.
63.Menkes JH, Kinsbourne M. Workshop on neurologic complications of pertussis and pertussis vaccinations. Neuropediatrics 1990; 21: 171-176.
64.Kiviravanta T, Airaksinen EM. Low sodium levels in serum are associated with febrile seizures. Acta Paediatr 1995; 84: 1372-1374.
65.Bar-Peled O et al. Distribution of glutamate transporter subtypes during human brain development. J Neurochem 1997; 69: 2571-2580.
66.Arauz-Contreas J, Feria-Velasco A. Monosodium-L-glutamate-induced convulsions 1. Differences in seizure pattern and duration of effect as a function of age in rats. Gen Pharmacol 1984; 15: 391-395.
67.Neil Z. Miller. Vaccines: Are they Really Safe and Effective? A Parent’s Guide to Childhood Shots. New Atlantean Press, NM 1999.
68.Toga Aw et al. Mapping brain maturation. Trend Neurosci 2006; 29: 148-159.
69.Gogtay N et al. Dynamic mapping of human cortical development during childhood and adolescence. Proc Natl Acad Sci USA 2006; 101: 8174-8179.
70.Jerigan TL, Tallal P. Late childhood changes in brain morphology observable with MRI. Dev Med Child Neurol 1990; 32: 379-385.
71.Maslinska D et al. Morphological forms and localizations of microglial cells in the developing human cerebellum. Folia Neuropathol 1998; 36: 145-151.
72.Monier A et al. Entry and distribution of microglial cells in human embryonic and fetal cerebral cortex. J Neuropathol Exp Neurol 2007; 66: 372-382.
73.Schwab JM et al. IL-6 is differentially expressed in the developing human fetal brain by microglial cells in zones of neuropoesis. In J Dev Neurosci 2001; 114: 232-241.
74.Schlett K. Glutamate as a modulator of embryonic and adult neurogenesis. Curr Top Med Chem 2006; 6: 949-960.
75.Kumuro H, Rakic P. Modulation of neuronal migration by NMDA receptors. Science 1993; 260: 95-97.
76.Marret S et al. Arrest of neuronal migration by excitatory amino acids in hamster developing brain. Proc Natl Acad Sci USA 1996; 93: 15463-15468.
77.Aarum J et al. Migration and differentiation of neural precursor cells can be directed by microglia. Proc Natl Acad Sci USA 2003;100: 15983-15988.
78.Ekdahl CT et al. Inflammation is detrimental for neurogenesis in adult brains. Proc Natl Acad Sci USA 2003; 100: 13632-13635.
79.Chao CC et al. Tumor necrosis factor-alpha potentates glutamate neurotoxicity in human fetal cell cultures. Dev Neurosci 1994; 16: 172-179.
80.Kemper TL et al. Neuropathology of infantile autism. J Neuropathology Exp Neurol 1998; 57: 645-652,
81.Bauman MI, Kemper TL. The neuropathology of autism spectrum disorders: What have we learned? Novartis Foundation Symp 2003; 251: 112-122.
82.Bauman M, Kemper TL. Developmental cerebellar abnormalities: a consistent finding in early infantile autism. Neurology 1986; 36 (Suppl 1): 190.
83.Courchesne E. Brainstem cerebellar and limbic neuroanatomical abnormalities in autism. Curr Opin Neurobiol 1997; 7: 269-278.
84.Buller KM, Day TA. Systemic administration of interleukin 1beta activates select populations of central amygdala afferents. J Comp Neurol 202; 452: 288-296.
85.Taylor DL et al. Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor -induced neurotoxicity in concert with microglial-derived Fas ligand. J Neurosci 2005; 25: 2952-2964.
86.Rothwell NJ. Cytokines-Killers in the brain? J Physiol 1999; 514.1: 3-17.
87.Samland H et al. Profound increase in sensitivity to glutamatergic –but not to cholinergic agonist-induced seizures in transgenic mice with astrocytes production of IL-6. J Neurosci Res 2003; 73: 176-187.
88.Bernardino L et al. Modulator effects of interleukin-1ß and Tumor necrosis factor- on AMPA-induced excitotoxicity in mouse organotypic hippocampal slice cultures. J Neurosci 2005; 25: 6734-6744.
89.Allan SM et al. Interleukin-1 and neuronal injury. Nature Reviews/Immunol 2005; 5: 629-640.
90.Burka SL et al. Maternal cytokine levels during pregnancy and adult psychosis. Brain Behav Immunol 2001; 15: 411-420.
91.Brown AS et al. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry 2004; 161: 889-895.
92.Ganguli R et al. Autoimmunity in schizophrenia: a review of recent findings. Ann Med 1993; 25: 489-496.
93.Schori H et al. Severe immunodeficiency has opposite effects in neuronal survival in glutamate-susceptible and resistant mice: adverse effect of B-cells. J Immunol 2002; 169: 2861-2865.
94.Cutrone R et al. Some oral polio vaccines were contaminated with infectious SV-40 after 1961. Can Res 2005; 65: 10273-10279.
95.Harasawa R, Tomiyama T. Evidence of pestivirus RNA in human virus vaccines. J Clin Microbiol 1994; 32: 1604-1605.
96.Geier M et al. Endotoxins in commercial vaccines. Appl Environ Microbiol 1978; 36: 445-449.
97.Giangaspero M et al. Genotypes of pestivirus RNA detected in live virus vaccines for human use. J vet Med Sci 2001; 63: 723-733.
98.Potts BJ et al. Possible role of pestivirus in microcephaly. Lancet 1987;1: 972-973.
99.Johnson JA, Heneine W. Characteristics of endogenous avian leukosis virus in chicken embryonic fibroblast substrates used in production of measles and mumps vaccine. J Virol 2001; 75: 3605-3612.
100.Gherardi RK et al. Macrophagic myofasciitis lesion assess long-term persistence of vaccine-derived aluminum hydroxide in muscle. Brain 2001; 124: 1821-1831.
101.Authier F-J et al. Central nervous system disease in patients with macrophagic myofasciitis. Brain 2001; 124: 974-983.
102.Bonnefont-Rousselot D et al. Blood oxidative status in patients with macrophagic myofasciitis. Biomed Pharmacol 2004; 58: 516-519.
103.Good PF et al. Selective accumulation of aluminum and iron in the neurofibrilary tangles of Alzheimer’s disease: a laser microprobe (LAMMA) study. Ann Neurol 1992; 31: 286-292.
104.Esparza JL et al. Aluminum-induced pro-oxidant effect in rats: protective role of exogenous melatonin. J Pineal Res 2003; 35: 32-39.
105.Yokel RA et al. The distribution of aluminum into and out of the brain. J Inorg Biochem 1999; 76: 127-132.
106.Campbell A et al. Chronic exposure to aluminum in drinking water increases inflammatory parameters selectively in the brain. J Neuroscience Res 2004; 75: 565-572.
107.Bishop NJ et al. Aluminum neurotoxicity in preterm infants receiving intravenous feeding solutions. N Engl J Med 1997; 336: 1557-1561.
108.Campbell A. Inflammation, neurodegenerative disease, and environmental exposures. Ann NY Acad Sci 2004; 1035: 117-132.
109.Shirabe T et al. Autopsy case of aluminum encephalopathy. Neuropathology 2002; 22: 206-210.
110.Armstrong RA et al. Hypothesis: Is Alzheimer’s disease a metal-induced immune disorder. Neurodegeneration 1995; 4: 107-111.
111.Flarend RE et al. In vivo absorption of aluminum-containing vaccine adjuvants using 26Al. Vaccine 1997; 15: 1314-1318.
112.Platt B et al. Aluminum toxicity in the rat brain: histochemical and immunocytochemical evidence. Brain Res Bull 2001; 55: 257-267.
113.Brookes N. Specificity and reliability of the inhibition by HgCl2 of glutamate transport in astrocytes cultures. J Neurochem 1988; 50: 1117-1122.
114.Vahter ME et al. Demethylation of methylmercury in different brain sites of Macaca fascicularis monkeys during long-term subclinical methylmercury exposure. Toxicol Appl Pharmacol 1995; 134: 273-284.
115.Charleston JS et al. Changes in the number of astrocytes and microglia in the thalamus of the monkey Macaca fascicularis following long-term subclinical methylmercury exposure. Neurotoxicology 1996; 17: 127-138.
116.Charleston JS et al. Increase in the number of reactive glia in the visual cortex of Macaca fascicularis following subclinical long-term methylmercury exposure. Toxicol Appl Pharmacol 1994; 129: 196-206.
117.Burbacher TM et al. Comparison of blood and brain mercury levels in infant monkeys exposed to methylmercury or vaccines containing thimerosal. Environ Health Perspect 2005; 113: 1015-1021.
118.Mutkus L et al. Methylmercury alters the in vitro uptake of glutamate and GLAST and GLT-1 transfected mutant CHO-K1 cells. Biol Trace Elem Res 2005; 107: 231-245.
119.Aschner M et al. Methymercury alters glutamate transport in astrocytes. Neurochem Int 2000; 37: 199-206.
120.Kim P, Choi BH. Selective inhibitors of glutamate uptake by mercury in cultured mouse astrocytes. Yonsi Med J 1995; 36: 299-305.
121.Kugler P, Schleyer V. Developmental expression of glutamate transporters and glutamate dehydrogenase in astrocytes of the postnatal rat hippocampus. Hippocampus 2004; 14: 975-985.
122.Yel L et al. Thimerosal induces neuronal cell apoptosis by causing cytochrome C and apoptosis-inducing factor release from mitochondria. In J Mol Med 2005; 16: 971-977.
123.Humphrey ML et al. Mitochondria mediated thimerosal-induced apoptosis in a human neuroblastoma cell line (SK-N-SH). Neurotoxicology 2005; 26: 407-416.
124.Henneberry RC. The role of neuronal energy in neurotoxicity of excitatory amino acids. Neurobiol Aging 1989; 10: 611-613.
125.Zeevalk GD et al. Excitotoxicity and oxidative stress during inhibition of energy metabolism. Dev Neurosci 1998; 20: 444-445.
126.Haley BE. The relationship of the toxic effects of mercury to exacerbation of the medical condition classified as Alzheimer’s disease. Medical Veritas 2007; 4: 1510-1524.
127.Sun YM et al. Sex-specific impairment in sexual and ingestive behaviors of monosodium glutamate-treated rats. Physiol Behavior 1991;50: 873-880.
128.Yang S-H et al. Testosterone increases neurotoxicity of glutamate in vitro and ischemia-reperfusion injury in an animal model. J Appl Physiol 2002; 92: 195-201.
129.Estrada M et al. Elevated testosterone induces apoptosis in neuronal cells. J Biol Chem 2006; 281: 25492-25501.
130.Aschner M et al. Involvement of glutamate and reactive oxygen species in methyl mercury neurotoxicity. Braz J Med Biol Res 2007; 40: 285-291.
131.Allen JM et al. The consequences of methylmercury exposure on interactive function between astrocytes and neurons. Neurotoxicology 2002; 23: 755-759.
132.Lautermilch NJ, Spitzer NC. Regulation of calcineurin by growth cone calcium waves controls neurite extension. J Neurosci 2000; 20: 315-325.
133.Estrada M et al. Ca2+ oscillations induced by testosterone enhance neurite outgrowth. J Cell Sci 2005; 119; 733-743.
134.Geier DA, Geier MR. A clinical trial of combined anti-estrogen and anti-heavy metal therapy in autistic disorder. Neuroendocrinol Lett 2006; 27: 833-838.
135.Baker AE et al. Estrogen modulates microglial inflammatory mediator production via interactions with estrogen receptor ß. Endocrinology 2004; 145: 5021-5032.
136.Wakefield AJ et al. Ileal-lymphoid nodular hyperplasia, non-specific colitis, and pervasive developmental disorders in children. Lancet 1998; 351: 637-641.
137.Ashwood P, Wakefiled AJ. Immune activation of peripheral blood and mucosal CD3+ lymphocyte cytokine profiles in children with autism and gastrointestinal systems. J Neuroimunol 2006; 173: 126-134.
138.Horvath K et al. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr 1999; 135: 559-563.
139.Afzal N et al. Constipation with acquired megacolon in children with autism. Pediatrics 2003; 112: 939-942.
140.Feingold SM et al. Gastrointestinal microflora studies in late-onset autism. Clin Infect Dis 2002; 35: S6-S16.
141.Vojdani A et al. Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumonia and Streptococcus group A. J Neuroimmunol 2002; 129: 168-177.
142.Lucarelli S et al. Food allergy and infantile autism. Panminerva Med 1995; 37: 137-141.
143.Knivsberg AM et al. A randomized, controlled study of dietary intervention in autistic syndrome. Nutri Neurosci 2002; 5: 251-261.
144.Vojdani A et al. Immune response to dietary proteins, gliadin and cerebellar peptides with autism. Nutr Neurosci 2004; 7: 151-161.
145.Whitely P et al. A gluten-free diet as an intervention for autism and associated disorders: preliminary findings. Autism 1999; m3: 45-65.
146.Bushara KO. Neurologic presentation of celiac disease. Gastroenterology 2005; 128: S92-S97.
147.Kinney HC et al. Degeneration of the central nervous system associated with celiac disease. J Neurol Sci 1982; 53: 9-22.
148.DeSantis A et al. Schizophrenia symptoms and SPECT abnormalities in a coelic patient: regression after gluten-free diet. J Intern Med 1997; 242: 421-423.
149.Beyenberg S et al. Chronic progressive leukoencephalopathy in adult celiac disease. Neurology 1998; 50: 820-822.
150.Burk K et al. Sporadic cerebellar ataxia associated with gluten sensitivity. Brain 2001; 124: 1013-1019.
151.Hu WT et al. Cognitive impairment and celiac disease. Arch Neurol 2006;63: 1440-1446.
152.Wakefield AJ et al. Review article: The concept of entero-colonic encephalopathy, autism and opioid receptor ligands. Aliment Pharmacol Ther 2002; 16: 663-674.
153.Peterson PK et al. The opioid-cytokine connection. J Neuroimmunology 1998; 83: 63-69.
154.Zhu L et al. Enhancing effect of beta-endorphins on glutamate toxicity. Zhongguo Yao Li Xue Bao 1998; 19: 108-111.
155.Blaylock RL. Interaction of cytokines, excitotoxins, and reactive nitrogen and oxygen species in autism spectrum disorders. JANA 2003; 6: 21-35.
156.Rao S, Ali U. Systemic fungal infections in neonates. J Postgrad Med 2005; 51 (suppl 1): S27-S29.
157.Sandler RH et al. Short term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol 2000; 15: 429-435.
158.Anderson T et al. NMDA-receptor antagonist prevents measles virus-induced neurodegeneration. Eur J Neurosci 1991; 3: 66-71.
159.Eastman CL et al. Increased brain quinolinic acid production in mice infected with a hamster neurotropic measles virus. Exp Neurol 1994;125: 119-124.
160.Raslet A et al. Borrelia burgdorferi induces inflammatory mediator production by murine microglia. J Neuroimmunol 2002; 130: 22-31.
161.Ma W eat al. Elevated cerebrospinal fluid levels of glutamate in children with bacterial meningitis as a predictor of the development of seizures or other adverse outcomes. Pediatr Crit care Med 2003; 4: 170-175.
162.Zhao Y et al. Eicopentaenoic acid prevents LPS-induced TNF- expression by preventing NFkB activation. J Amer Coll Nutr 2004; 23: 71-78.
163.Weldon SM et al. Docosahexaenoic acid induces an anti-inflammatory profile in liposaccharide-stimulated THP-1 macrophage mice more effectively than eicosapentaenoid acid. J Nutr Biochem 2007; 18: 250-258.
164.Katayama Y et al. Detection of measles virus nucleoprotein mRNA in autopsied brain tissue. J Gen Virol 1995; 76: 3201-3204.
165.Katayama Y et al. Detection of measles virus mRNA from autopsied human tissues. J Clin Microbiol 1998; 36: 299-301.
166.Hult B et al. Neurobiology of HIV. Int Rev Psychology 2008; 20: 3-13.
167.Gonzales-Sarano F, Martin-Garcia J. the neuropathogenesis of AIDS. Nat Rev Immunol 2005; 5: 69-81.
168.Rubin SA et al. Viral teratogenesis: brain developmental damage associated with maturation state at time of infection. Brain Dev Rev 1999; 112: 237-244.
169.Lellouch-Tubiana A et al. Immunocytochemical characterization of long-term persistent immune activation in human brain after herpes simplex encephalitis. Neuropathology Appl Neurobiol 2000; 26: 285-294.
170.Ovanesov MV et al. Activation of microglia by Borna disease virus infection: In vitro study. J Virol 2006; 80: 12141-12148.
171.Volmer R et al. Borna disease virus infection impairs synaptic plasticity. J Virol 2007; 81: 8833-8837.
172.De la Torre JC. Borna virus and the brain. J Infect Dis 2002; 186: (suppl2) : S241-S247.